Recent Research Analysts’ Ratings Changes for Aratana Therapeutics (PETX)

A number of research firms have changed their ratings and price targets for Aratana Therapeutics (NASDAQ: PETX):

  • 12/31/2017 – Aratana Therapeutics was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 12/27/2017 – Aratana Therapeutics is now covered by analysts at CL King. They set a “neutral” rating on the stock.
  • 12/21/2017 – Aratana Therapeutics was given a new $10.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 12/18/2017 – Aratana Therapeutics had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $6.00 price target on the stock.
  • 11/18/2017 – Aratana Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “
  • 11/17/2017 – Aratana Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $10.00 price target on the stock.
  • 11/16/2017 – Aratana Therapeutics was given a new $9.00 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 11/9/2017 – Aratana Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $7.75 price target on the stock. According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “

Aratana Therapeutics Inc (NASDAQ:PETX) traded down $0.05 during midday trading on Thursday, hitting $5.28. The stock had a trading volume of 276,500 shares, compared to its average volume of 291,850. Aratana Therapeutics Inc has a 12 month low of $4.85 and a 12 month high of $8.63. The firm has a market capitalization of $227.47, a PE ratio of -3.64 and a beta of 3.36. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.08 and a current ratio of 3.42.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.03. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The company had revenue of $6.16 million during the quarter, compared to analysts’ expectations of $6.47 million. During the same period in the previous year, the firm posted ($0.38) earnings per share. The business’s revenue for the quarter was up 1440.0% compared to the same quarter last year. analysts forecast that Aratana Therapeutics Inc will post -1.03 EPS for the current fiscal year.

In other news, insider Peter Steven St sold 50,000 shares of Aratana Therapeutics stock in a transaction on Friday, November 10th. The stock was sold at an average price of $7.00, for a total value of $350,000.00. Following the completion of the sale, the insider now owns 529,359 shares of the company’s stock, valued at $3,705,513. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Healthcare Master Fun Broadfin sold 116,516 shares of Aratana Therapeutics stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $6.53, for a total value of $760,849.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,057,032 shares of company stock valued at $6,186,791. Company insiders own 5.20% of the company’s stock.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Receive News & Ratings for Aratana Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.